Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT03087916 Recruiting - Clinical trials for Major Depressive Disorder (MDD)

Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder

Start date: June 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran.

NCT ID: NCT03084744 Recruiting - Dysthymic Disorder Clinical Trials

Schema Therapy for Chronic Depression

Start date: August 21, 2017
Phase: N/A
Study type: Interventional

To compare the efficacy of schema therapy versus active monitoring for women with chronic depression receiving psychiatric care.

NCT ID: NCT03084042 Recruiting - Clinical trials for Major Depressive Disorder

Emotional Brain Networks & Cognitive Functioning in Depression and Anxiety

Start date: July 2016
Phase:
Study type: Observational

This study aims to 1) examine common and specific emotional and cognitive dysfunctions between Major Depression and generalized anxiety disorder; 2) Examine emotional and cognitive dysfunctions between the two disorders and healthy controls; 3) Examine the biomarkers predicting successful therapy or not.

NCT ID: NCT03069118 Recruiting - Clinical trials for Alcohol Use Disorder

90-Day Online Substance Use Program

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Individuals indicating risky substance use are randomly assigned either to a three-month online intervention on the Workit Health platform or a waitlist/treatment as usual. Those randomized to treatment will report reduced consumption of alcohol and other drugs and higher quality of life at study conclusion.

NCT ID: NCT03064477 Recruiting - Anxiety Disorders Clinical Trials

The Unified Protocol for the Treatment of Emotional Disorders in Spanish Public Mental Health System

Start date: September 14, 2014
Phase: N/A
Study type: Interventional

The present randomized, controlled trial will compare the cost-efficacy and acceptability of the Unified Protocol in group format against traditional individual Cognitive Behavioral Treatment in a sample of patients with emotional disorders. Ultimately, the goal of the current study is to explore whether the Unified Protocol in group format can be a cost-effective psychological intervention for emotional disorders in the Spanish National Health System, that is, one that generates long-lasting changes in symptoms, while reducing both direct and indirect economic costs associated with the treatment of emotional disorders.

NCT ID: NCT03062332 Recruiting - Clinical trials for Major Depressive Disorder

The Gut Microbiota of Bipolar and Depression

Start date: January 16, 2020
Phase:
Study type: Observational

Background: The gut microbiome is emerging as an important factor in regulating mental health yet it remains unclear what the target should be for psychiatric treatment. Investigators aim at elucidating the complement of the gut microbiome community for individuals with Major Depressive disorder (MDD) and Bipolar disorder (BD) relative to controls, and test for relationships with symptoms. Methods: Investigators prospect to recruit subjects including patients and controls amount to 240. All subjects will be collected for blood and stool samples,assessed by clinical scales. Finally, analyzing the correlation among the metabolon in blood, microbiota in stool and clinical scales to obtain the possible interaction between diseases and gut microbiota.

NCT ID: NCT03029494 Recruiting - Clinical trials for Temporomandibular Disorders

Oxidative Stress and Opiorphin in Temporomandibular Disorders

ROStrO-TMD
Start date: October 1, 2015
Phase: N/A
Study type: Interventional

The objective of this study is to quantify salivary oxidative stress biomarkers in patients with temporomandibular disorders and to quantify recently isolated endogenous peptide opiorphin in saliva of these patients. As chronic exposure to stress may cause hyperalgesia as a result of the stress response in the hypothalamic-pituitary-adrenal axis, aim is to test this as an underlying mechanism by correlating opiorphin and oxidative stress markers to salivary cortisol levels. The aim is to assess the association of oxidative stress salivary biomarkers with muscle and joint pain and to measure opiorphin, a potential biomarker of different pathological states.

NCT ID: NCT03022942 Recruiting - Copd Clinical Trials

Efficacy of Costal Mobilization Techniques and Manual Diaphragm Release Technique in Patients COPD

Start date: January 2017
Phase: N/A
Study type: Interventional

To evaluate the acute and chronic effects of costal mobilization techniques and diaphragmatic release in chest cavity kinematics, diaphragmatic mobility and functional capacity in patients with chronic obstructive pulmonary disease

NCT ID: NCT03019432 Recruiting - Stroke Clinical Trials

Perception of Verticality After Stroke

Start date: January 2017
Phase: N/A
Study type: Observational

In this study, the researchers will investigate whether the E-effect is present in stroke subjects both on the subjective visual and postural vertical test. In addition, researchers will investigate the impact of the loss of different sensory information sources on the sensory reweighting strategies and perception of verticality by measuring the effect of somatosensory loss on the E-effect.

NCT ID: NCT03012724 Recruiting - Clinical trials for Major Depressive Disorder (MDD)

Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)

Start date: March 30, 2017
Phase: N/A
Study type: Interventional

The purpose of the study is to demonstrate that the efficacy and safety of deep brain rTMS, (Transcranial Magnetic Stimulation) H7-Coil treatment as add on treatment, is as good as the FDA cleared, H1-Coil, in subjects with major depressive disorder that have been previously unsuccessfully treated with antidepressant medications.